ALCHEMIA SHARES PLUNGE

ALCHEMIA SHARES PLUNGE

SHARES in Alchemia (ASX:ACL) have dived 83 per cent after the company announced its metatastic colorectal cancer trial had failed.

The treatment tested Alchemia’s HyAct technology formulated with chemotherapeutic drug irinotecan over using irinotecan alone.

HA-irinotecan did not improve progression free survival in patients.

Alchemia CEO Thomas Liquard says the company will conduct an in-depth review of the trial.

“We are extremely disappointed in the outcome of this trial and extend our appreciation to trial investigators, the clinical sites and the hundreds of patients who participated in this study,” Liquard says.

“We expect to report back to the scientific community and the market with further details on our data reviews and corporate strategy early in 2015.”

The drug development company’s financial position includes $8.9 million in cash and a $6.5 million research and tax development tax incentive to be received next month.

ACL is trading at $0.098 per share.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Does your pay structure answer today's challenges?
Partner Content
If you are not reassessing how your organisation remunerates and rewards employees as a...
Aon
Advertisement

Related Stories

Shine launches class action against QSuper

Shine launches class action against QSuper

Members of QSuper have filed a class action against the super fund ...

Nic Blair's digital healthcare startup Midnight Health scores $4m investment from nib

Nic Blair's digital healthcare startup Midnight Health scores $4m investment from nib

Health insurer nib (ASX: NHF) has put its weight behind healthcare ...

Reprieve for EML Payments as Irish regulators allow new customers and programs

Reprieve for EML Payments as Irish regulators allow new customers and programs

The dreaded 'Bank of Ireland Update' has become an ominous ...

GURNER, Qualitas raise $1.2 billion for rent-to-build platform

GURNER, Qualitas raise $1.2 billion for rent-to-build platform

Developer GURNER and alternative real estate investment manager Qua...